Nephrocare Health Services Limited has informed the Exchange about change in Management
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 2.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nephrocare Health Services (NephroPlus) informed exchanges about the outcome of its board meeting held on January 5, 2026. The board approved the re-appointment of Mr. Om Prakash Manchanda (DIN: 02099404) as an Independent Director for a second 3-year term, from February 11, 2026 to February 10, 2029, subject to shareholder approval. Mr. Manchanda has been on the board since February 2021 and has nearly 35 years of experience, including a stint as former Managing Director of Dr. Lal Path Labs. The board also approved the appointment of M/s Makarand M. Joshi & Co., a Mumbai-based firm of practicing company secretaries, as the new Secretarial Auditor for a 5-year period from April 1, 2025 to March 31, 2030, pending shareholder approval.
These are routine corporate governance actions and are unlikely to have a material impact on the stock price. Continuity is maintained with the re-appointment of an experienced independent director, while a new secretarial auditor strengthens compliance oversight.